The FDA has cleared GSK's PD-1 inhibitor Jemperli as a treatment for all adult patients with primary advanced or recurrent endometrial cancer, a key part of the company's growth ambitions for the ...

Women in England with a specific type of endometrial cancer will be able to access an immunotherapy for the first time, after NICE backed use of GlaxoSmithKline's PD-1 inhibitor Jemperli via the ...

Jemperli (Dostarlimab): GlaxoSmithKline Jemperli (dostarlimab) is an anti-PD-1 monoclonal antibody developed by GlaxoSmithKline that has been approved for use in advanced or recurrent endometrial ...

GSK and the University of Oxford have entered a new research partnership to launch an immuno-prevention programme.

Harvey Jones isn't having much fun playing the GSK share price game. The FTSE 100 pharmaceutical stock must work hard to make ...

Also in Europe, officials have endorsed GSK's Jemperli to treat all adult patients with primary advanced or recurrent endometrial cancer, including those with mismatch repair proficient (MMRp ...

In light of the controversy surrounding the benefits and risks of lymphadenectomy in patients with endometrial cancer there is increasing interest in minimal and non invasive techniques to ...

The majority of women with uterine fibroids are asymptomatic, consequently get less clinical attention and fibroid tumors often remain undiagnosed. [23,24] Symptomatic women typically complain ...

GSK (GSK) announced that the European Medicines Agency, EMA, has accepted for review the Marketing Authorisation Application, MAA, for the use ...

Jan. 30, 2025 — A new study shows that artificial intelligence (AI) can help doctors make better decisions when treating cancer. However, it also highlights challenges in how doctors and AI work ...